In vivo correction of genetic defects of monocyte/macrophages using attenuated Salmonella as oral vectors for targeted gene delivery

Gene Therapy

Volumn 7, Issue 20, 2000, Pages 1725-1730

  Paglia, P ^a   Terrazzini, N ^a   Schulze, K ^c   Guzman C A ^b   Colombo, M P ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^c NONE

Author keywords

Gene therapy; GKO mice; IFN ; Inherited disease; Salmonella

Indexed keywords

GAMMA INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; EXPRESSION VECTOR; FEMALE; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC CODE; GENETIC DISORDER; IMMUNE DEFICIENCY; IN VIVO STUDY; INFECTION RESISTANCE; MACROPHAGE; MICROBIAL ATTENUATION; MONOCYTE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; SALMONELLA; TRANSGENE;

ANIMALIA; BACTERIA (MICROORGANISMS); EUKARYOTA; MURINAE; NEGIBACTERIA; SALMONELLA;

EID: 0033758836     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301290     Document Type: Article

References (30)

1. Prospects for gene therapy of neutrophil defects
2. The molecular basis of chronic granulomatous disease
3. New therapeutic prospects for the glycosphingolipid lysosomal storage diseases
4. Functional gene transfer from intracellular bacteria to mammalian cells
5. Bacteria as gene delivery vectors for mammalian cells
6. Attenuated shigella as a DNA delivery vehicle for DNA-mediated immunization
7. Use of Salmonella for heterologous gene expression and vaccine delivery systems
8. Oral somatic transgene vaccination using attenuated S. typhimurium
9. Salmonella vaccine carrier strains: Effective delivery system to trigger anti-tumor immunity by oral route
10. Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimurium, results in protective immunity against a murine fibrosarcoma
11. Salmonellosis: Host immune responses and bacterial virulence determinants
12. Vector development: A major obstacle in human gene therapy
13. Viral vectors for gene therapy
14. Glycoprotein lysosomal storage disorders: Alpha- and beta-mannosidosis, fucosidosis and alpha-N-acetylgalactosaminidase deficiency
15. The hereditary hemochromatosis gene (HFE): A MHC class I-like gene that functions in the regulation of iron homeostasis
16. Role of interferon-gamma in the pathogenesis of LCMV-induced meningitis: Unimpaired leucocyte recruitment, but deficient macrophage activation in interferon-gamma knock-out mice
17. Interferon-gamma receptor-deficient mice exhibit impaired gut mucosal immune responses but intact oral tolerance
18. Wild type Hfe protein normalizes transferrin iron accumulation in macrophages from subjects with hereditary hemochromatosis
19. The defined attenuated listeria monocytogenes delta mp12 mutant is an effective oral vaccine carrier to trigger a long-lasting immune response against a mouse fibrosarcoma
20. Attenuated Listeria monocytogenes carrier strains can deliver an HIV-1 gp120 T helper epitope to MHC class II-restricted human CD4+ T cells
21. Delivery of DNA vaccines by attenuated intracellular bacteria
22. Phase I clinical trials of aroA aroD and aroA aroD htrA attenuated S. typhi vaccines; effect of formulation on safety and immunogenicity
23. A galE via (Vi antigen-negative) mutant of Salmonella typhi Ty2 retains virulence in humans
24. Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in humans
25. Human gene targeting by viral vectors
26. Pathogenicity island 2 mutants of Salmonella typhimurium are efficient carriers for heterologous antigens and enable modulation of immune responses
27. Regulation of host immune responses by modification of Salmonella virulence genes
28. Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency
29. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients
30. Cell therapy: Achievements and perspectives